Paloma Partners’s Ovid Therapeutics OVID Stock Holding History

Paloma Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-59,100	Closed	-$109K	–	2190
2019 Q2	$109K	Buy	+59,100	New	+$106K	﹤0.01%	1617

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's OVID Position: Q3 2019 in Review

Paloma Partners sold out of Ovid Therapeutics (OVID) in Q3 2019, closing a stake of 59,100 shares — an estimated $109K sold.

Paloma Partners first reported a position in OVID in Q2 2019 and held it in 1 quarter. The position peaked at $109K in Q2 2019. 38 funds tracked by Wall St. Rank hold OVID as of Q3 2019.

Paloma Partners reported no remaining Ovid Therapeutics position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 59,100 Ovid Therapeutics shares in Q3 2019, an estimated $109K.
Paloma Partners first reported a position in Ovid Therapeutics in Q2 2019 and held it in 1 quarter.
Paloma Partners's Ovid Therapeutics position peaked at $109K in Q2 2019.
38 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.